(Q38254745)

1 September 2017

1 reference

title

Therapies for inter-relating diabetes and obesity - GLP-1 and obesity (English)

1 reference

1 September 2017

0 references

Signe Sørensen Torekov

object named as

Signe S Torekov

series ordinal

2

0 references

Jens Juul Holst

object named as

Jens J Holst

series ordinal

3

0 references

Eva Pers Winning Iepsen

object named as

Eva W Iepsen

series ordinal

1

0 references

language of work or name

English

0 references

publication date

26 September 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

17

1 reference

1 September 2017

2487-2500

1 reference

Global burden of obesity in 2005 and projections to 2030.

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Diabesity: an overview of a rising epidemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Obesity and type 2 diabetes: what can be unified and what needs to be individualized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

On the physiology of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucagon-like peptide 1(GLP-1) in biology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Neural regulation of glucagon-like peptide-1 secretion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucagon-like peptide 1 and the brain: central actions-central sources?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Pharmacological management of appetite expression in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Role of leptin in the regulation of glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Obesity and leptin resistance: distinguishing cause from effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Emerging role of GLP-1 receptor agonists in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Benefit-risk assessment of orlistat in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Bariatric surgery: a systematic review and network meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The effect of glucagon-like peptide 1 on cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Mild renal impairment and the efficacy and safety of liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Exenatide therapy in insulin-treated type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.965678

10.1517/14656566.2014.965678

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25260877